Used in cancer research as a dual inhibitor targeting epidermal growth factor receptor (EGFR) and cyclin-dependent kinase 2 (CDK2). It shows potential in blocking signaling pathways involved in tumor cell proliferation and survival, particularly in non-small cell lung cancer and other solid tumors. Its ability to simultaneously inhibit both EGFR and CDK2 makes it a valuable tool compound for studying cell cycle regulation and tyrosine kinase signaling in oncology drug development.